March 3, 2018 is Triple-Negative Breast Cancer Day. We have known for a while that not all breast cancer is created equal. Most breast cancer is ‘hormone-fueled’, meaning that the cancer cells have estrogen and variably progesterone receptors on their cell surface, and are stimulated to replicate by circulating hormones in the blood. When these hormone receptors and another type of receptor (called HER2) are missing, the cancer is termed “Triple-Negative Breast Cancer.” Because of its triple negative status, triple negative tumors generally do not respond to receptor targeted treatments. Depending on the stage of its diagnosis, triple negative breast cancer can be particularly aggressive, and more likely to recur than other subtypes of breast cancer, hence chemotherapy is almost always used in its treatment.
Daniel J Farrugia MD PhD Administrator
Director, Centegra Comprehensive Breast Program
Daniel Farrugia MD PhD is a fellowship-trained breast surgeon in the northern suburbs of Chicago. He is Director of the Centegra Comprehensive Breast Program. His research in breast cancer has been published in top international journals, and has been cited over a thousand times in the medical literature.